RIAMET

This brand name is authorized in Austria, Australia, France, Japan, Netherlands, New Zealand, United Kingdom

Active ingredients

The drug RIAMET contains a combination of these active pharmaceutical ingredients (APIs):

1 Artemether UNII C7D6T3H22J - ARTEMETHER

Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas. Read about Artemether

2 Lumefantrine UNII F38R0JR742 - LUMEFANTRINE

Read about Lumefantrine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RIAMET Tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
P01BF01	Artemether and lumefantrine	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BF Artemisinin and derivatives, combinations
Discover more medicines within P01BF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 5296R, 9498X
Country: FR	Base de données publique des médicaments	Identifier(s): 65574434
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 26594
Country: JP	医薬品医療機器総合機構	Identifier(s): 6419102F1024
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 59331
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 14003, 9649